Ambuja Cement

Accumulate



View: Fair valuation; maintain Accumulate

- Revenue, APAT and volumes were above estimates whereas realizations and EBITDA/tn in line.
- ACEM posted 12.1% YoY growth in revenue to Rs35.2 bn due to 7.2% YoY volume growth to 7.0 mt and +4.6% YoY (-0.3% QoQ) realization growth to Rs5,014. EBITDA increased by 40.3% YoY to Rs7.7 bn and APAT increased by 65.7% YoY to Rs5.0 bn. ACEM has declared dividend of Rs1/ share along with an interim dividend of Rs17/sh in Oct'20, resulting in huge cash outflow Rs36.6 bn in CY20. Cash on books as on Dec'20 stood at Rs29.2 bn.
- We expect 9.4%/ 8.2%/ 5.7% revenue/ EBITDA/ APAT CAGR over CY20-22E led by 13.8%/ 4.5% volume growth and -0.3%/ 1.0% cement realization growth in CY21E/ CY22E.
- We broadly maintain our CY21E/ CY22E estimates. The full benefit of uptick in volumes from planned expansion (3.1mtpa clinker and 1.8mtpa grinding at Marwar Mundwa in Rajasthan) will come in CY22E.
- The stock has run up 11% since our Q3CY20 result update note dated 22 Oct'20 thus leaving limited upside. Thus, we maintain Accumulate with a revised TP of Rs290 based on (12x standalone CY22E EV/EBITDA) and ACEM's 50% stake in ACC at 20% holding discount.

EBITDA/tn up 30.9%/ -8.7% YoY/ QoQ

Higher than estimated volume (+7.2% YoY/ +23.6% QoQ to 7.0 mt), in line realization (+4.6% YoY/ -0.3% QoQ to Rs5,014/tn), combined with in line operating cost/tn (-1.0% YoY/ +2.3% QoQ to Rs3,919) helped ACEM to post strong 30.9% YoY growth in EBITDA/tn to Rs1,095/tn. For CY20, EBITDA/tn grew 30.4% YoY to Rs1,170/ tn led by 3.1% YoY realization growth to Rs5,025/ tn coupled with lower cost/tn of 3.0% YoY to Rs3,856/ tn.

Q4CY20 Result (Rs Mn)

Particulars	Q4CY20	Q4CY19	YoY (%)	Q3CY20	QoQ (%)
Revenue	35,151	31,359	12.1	28,525	23.2
Total Expense	27,473	25,885	6.1	21,721	26.5
EBITDA	7,678	5,474	40.3	6,803	12.9
Depreciation	1,257	1,487	(15.4)	1,287	(2.3)
EBIT	6,421	3,987	61.0	5,517	16.4
Other Income	394	656	(39.9)	523	(24.5)
Interest	233	237	(1.6)	185	26.2
EBT	6,583	4,407	49.4	5,855	12.4
Tax	1,612	(142)	(1232.7)	1,450	11.2
RPAT	4,971	4,549	9.3	4,405	12.8
APAT	4,971	3,000	65.7	4,405	12.8
			(bps)		(bps)
Gross Margin (%)	42.6	40.4	221	45.0	(239)
EBITDA Margin (%)	21.8	17.5	439	23.9	(201)
NPM (%)	14.1	14.5	(36)	15.4	(130)
Tax Rate (%)	24.5	(3.2)	2771	24.8	(27)
EBIT Margin (%)	18.3	12.7	555	19.3	(107)

CMP		F	Rs 283			
Target / Upside	Rs 290 / 3%					
NIFTY		1	5,119			
Scrip Details						
Equity / FV	Rs 3,9	71mn	/ Rs 2			
Market Cap		Rs 562bn				
		US	D 8bn			
52-week High/Low		Rs 291	L/ 137			
Avg. Volume (no)		77,4	4,270			
Bloom Code		AC	EM IN			
Price Performance	1M	3M	12M			
Absolute (%)	8	9	37			
Rel to NIFTY (%)	4	(8)	13			

Shareholding Pattern

	Jun'20	Sep'20	Dec'20
Promoters	63.3	63.3	63.3
MF/Banks/FIs	13.6	13.3	11.5
FIIs	16.3	16.8	18.1
Public / Others	6.9	6.7	7.1

Valuation (x)

	CY20A	CY21E	CY22E
P/E	31.4	30.2	28.1
EV/EBITDA	20.1	18.6	16.7
ROE (%)	8.4	8.8	8.9
RoACE (%)	8.7	9.1	9.1

Estimates (Rs mn)

	CY20A	CY21E	CY22E
Revenue	1,13,719	1,28,976 1	L,36,144
EBITDA	26,466	28,567	31,002
PAT	17,901	18,586	20,014
EPS (Rs.)	9.0	9.4	10.1

VP Research: Shravan Shah Tel: +91 22 40969749 E-mail: shravans@dolatcapital.com

Associate: Maulik Shah Tel: +91 22 40969775 E-mail: mauliks@dolatcapital.com

Associate: Parth Bhavsar Tel: +91 22 40969775 E-mail: parthb@dolatcapital.com



Key highlights from management presentation

ACEM has renewed existing Master Supply Agreement ('MSA') with ACC for a period of 3 years w.e.f. May 03, 2021, on the same terms and conditions of the existing MSA. Cement industry has strong linkages with other sectors such as Infrastructure, Real Estate, Housing and Commercial segment. Post recovery from COVID-19, it is expected that cement demand will grow in range of 15-17% YoY for CY21.

Exhibit 1: Actual V/s DART estimates (Rs mn)

Exhibit 1. Actual 1/3 Drill C	othinaces (no inin	1		
Particulars	Actual	DART Est		Comments
Revenue (Rs mn)	35,151	33,391		+5.1%/ +0.2% higher/ higher than estimated volume/ realization
EBITDA (Rs mn)	7,678	7,272	5.6	+0.2%/ +0.1% higher/ higher than estimated realization/ cost
EBITDA%	21.8	21.8	7 bps	
PAT (Rs mn)	4,971	4,279	16.2	Led by lower depreciation and interest cost coupled with higher other income

Source: Company, DART

Exhibit 2: Change in estimates - Broadly maintain CY21E/ CY22E estimates

(Rs mn)		CY21E		CY22E			
	New	Old	% change	New	Old	%change	
Net revenues	1,28,976	1,24,569	3.5	1,36,144	1,32,775	2.5	
EBIDTA	28,567	28,089	1.7	31,002	30,127	2.9	
EBIDTA margin (%)	22.1	22.5	(40)	22.8	22.7	8	
Adj. Net Profit	18,586	17,502	6.2	20,014	19,211	4.2	
EPS (`)	9.4	8.8	6.2	10.1	9.7	4.2	

Source: DART, Company

Key earnings takeaways

Demand

- Demand continues to be strong and rural India continues to outperform vs.
 Urban India. Megatrends for demand continue to be increasing population, nuclearisation, increasing urbanization and govt. focus.
- Expect strong demand rebound in CY21E. Expect industry demand to grow by 15-17% from 295-300mt in CY20 to 345-350mt in CY21E. Utilization of cement industry is expected to remain high.
- Ambuja's focus will be on retail segment and to increase market share via volumes.
- Increase in demand in CY21E will come from Housing, Infra and Industrial & Commercial segment. CY21E volumes are expected to grow 5-7% vs. CY19 and double digit growth in CY21E vs. CY20.
- Current utilization is 80%+.
- Trade segment is 80% and premium cement is 12% in Q4CY20 vs. 8% in Q1CY20 of trade segment in Q4CY20. Premium cement has increased 16% YoY.
- 'Kawach' a premium cement brand is an expensive product (Rs50/ bag higher vs. base product). Fixed price for entire year.
- MSA agreement helped Ambuja increase its utilization levels and helped ACC to increase its volumes. MSA led to direct addition of Rs2.5 bn to EBITDA. MSA will help to add 5%+/ 5% on PBT levels to Ambuja/ ACC.



- Ambuja directionally moving towards increase in market share.
- Will utilize underutilized grinding capacities between ACC and Ambuja.

Cost

- Ambuja has saved Rs200/tn in CY20 led by cost efficiencies like "I CAN program" and MSA.
- Ambuja doesn't keep petcoke inventory of more than 2-3 months as they don't believe in speculation.
- Will absorb fly ash in North region to help manage clinker factor.
- Other expenses will increase with increase in volumes.

Expansion & Capex

- Expect Marwar Mundwa plant (1.8mtpa GU + 3mtpa Clinker) to commission by Jun'21. Volumes will accelerate post this expansion and expect full ramp up in CY22E.
- Post Marwar Mundwa plant, Ambuja's plans are underway where they have base for raw materials, Like they plan to utilize Bhatapara raw materials to expand in East and Maratha raw materials to expand in West regions. Ambuja has enough money to fund capex even after paying huge dividend (Rs.17+1/share).
- Expect green power contribution to increase from 5% (CY20) to 38% (CY22E). Expect WHRS capacity to increase from 2% now to 21%+ by CY22E. 54MW WHRS plants in Darlaghat, Bhatapara and Marwar Mundwa will commence by CY22E. Couple of plants are expected to commence in Ambuja Nagar and Maratha as well. Capex for WHRS plants is Rs90mn per MW. Solar capacity contribution is also expected to move higher than 15%.
- Current WHRS capacity is 6.5 MW and 53.4 MW capex is going on and expect additional 30 MW soon. Current TPP capacity is 291 MW.
- Will focus on clinker factor in CY21E as well as on special products and premium cement.
- By end of CY21E, will decide on new capex plans.
- Greenfield expansion takes 15-16 months to commence once land is secured and brownfield takes 12-13 months to commence.



Exhibit 3: Income statement (standalone)

Rs mn	Q4CY20	Q4CY19	YoY (%)	Q3CY20	QoQ (%)	CY20	CY19	YoY (%)
Revenue from operation	35,151	31,359	12.1	28,525	23.2	1,13,719	1,16,732	(2.6)
Other Operating Income	0	0	-	0	-	0	0	-
Total Revenue	35,151	31,359	12.1	28,525	23.2	1,13,719	1,16,732	(2.6)
Raw Material Cost	4,486	3,633	23.5	2,547	76.1	11,863	11,255	5.4
Employee Expenses	1,850	1,690	9.5	1,622	14.0	6,688	6,726	(0.6)
Power and Fuel	7,010	6,692	4.7	5,749	21.9	22,519	25,864	(12.9)
Freight Cost	8,690	8,377	3.7	7,404	17.4	28,549	30,942	(7.7)
Other expenses	5,437	5,493	(1.0)	4,400	23.6	17,634	20,456	(13.8)
Total Expenditure	27,473	25,885	6.1	21,721	26.5	87,253	95,243	(8.4)
PBIDT (Excl. OI)	7,678	5,474	40.3	6,803	12.9	26,466	21,489	23.2
Other Income	394	656	(39.9)	523	(24.5)	3,720	4,265	(12.8)
Depreciation	1,257	1,487	(15.4)	1,287	(2.3)	5,212	5,438	(4.2)
EBIT	6,816	4,643	46.8	6,039	12.9	24,974	20,315	22.9
Interest	233	237	(1.6)	185	26.2	831	835	(0.6)
PBT (Excl. Exceptional Items)	6,583	4,407	49.4	5,855	12.4	24,144	19,480	23.9
Exceptional Items	0	0	-	0	-	0	0	-
PBT (Incl. Exceptional Items)	6,583	4,407	49.4	5,855	12.4	24,144	19,480	23.9
Tax	1,612	(142)	-	1,450	11.2	6,242	4,195	48.8
RPAT	4,971	4,549	9.3	4,405	12.8	17,901	15,285	17.1
Adjustment	0	(1,549)	-	0	-	0	-1,549	-
APAT	4,971	3,000	65.7	4,405	12.8	17,901	13,737	30.3
Adj. EPS (Rs)	2.50	1.51	65.7	2.22	12.8	9.02	6.92	30.3
			bps		bps			bps
EBIDTA Margin (excl. O.I.)	21.8	17.5	439	23.9	(201)	23.3	18.4	486
Tax Rate (%)	24.5	(3.2)	-	24.8	(27)	25.9	21.5	432
NPM (%)	14.1	9.6	457	15.4	(130)	15.7	11.8	397

Source: Company, DART

Exhibit 4: Volume, Realization and Cost/tn Analysis

Particulars	Q4CY20	Q4CY19	YoY (%)	Q3CY20	QoQ (%)	CY20	CY19	YoY (%)
Volume (mt)	7.0	6.5	7.2	5.7	23.6	22.6	24.0	(5.6)
Realization/tn (Rs)	5,014	4,795	4.6	5,031	(0.3)	5,025	4,872	3.1
EBITDA/ tn (Rs)	1,095	837	30.9	1,200	(8.7)	1,170	897	30.4
Cost/ tn (Rs)	3,919	3,958	(1.0)	3,831	2.3	3,856	3,975	(3.0)
Raw Material Cost/ tn (Rs)	640	555	15.2	449	42.5	524	470	11.6
Employee Expenses/ tn (Rs)	264	258	2.1	286	(7.8)	296	281	5.3
Power and Fuels/ tn (Rs)	1,000	1,023	(2.3)	1,014	(1.4)	995	1,079	(7.8)
Freight Expenses/ tn (Rs)	1,240	1,281	(3.2)	1,306	(5.1)	1,262	1,291	(2.3)
Other expenses/ tn (Rs)	776	840	(7.7)	776	(0.0)	779	854	(8.7)

Source: Company, DART

Exhibit 5: % of Revenue

CY20	Q4CY19	YoY (%)	Q3CY20	QoQ (%)	CY20	CY19	YoY (%)
12.8	11.6	118	8.9	383	10.4	9.6	79
5.3	5.4	(13)	5.7	(42)	5.9	5.8	12
19.9	21.3	(140)	20.2	(21)	19.8	22.2	(235)
24.7	26.7	(199)	26.0	(123)	25.1	26.5	(140)
15.5	17.5	(205)	15.4	4	15.5	17.5	(202)
	12.8 5.3 19.9 24.7 15.5	12.8 11.6 5.3 5.4 19.9 21.3 24.7 26.7	12.8 11.6 118 5.3 5.4 (13) 19.9 21.3 (140) 24.7 26.7 (199)	12.8 11.6 118 8.9 5.3 5.4 (13) 5.7 19.9 21.3 (140) 20.2 24.7 26.7 (199) 26.0	12.8 11.6 118 8.9 383 5.3 5.4 (13) 5.7 (42) 19.9 21.3 (140) 20.2 (21) 24.7 26.7 (199) 26.0 (123)	12.8 11.6 118 8.9 383 10.4 5.3 5.4 (13) 5.7 (42) 5.9 19.9 21.3 (140) 20.2 (21) 19.8 24.7 26.7 (199) 26.0 (123) 25.1	12.8 11.6 118 8.9 383 10.4 9.6 5.3 5.4 (13) 5.7 (42) 5.9 5.8 19.9 21.3 (140) 20.2 (21) 19.8 22.2 24.7 26.7 (199) 26.0 (123) 25.1 26.5

Source: Company, DART




Exhibit 6: Valuation

Particulars	(Rs mn)
Assumed EV/EBITDA multiple (x)	12
EBITDA (CY22E)	31,002
EV	3,72,024
Less: Net Debt (CY22E)	(42,783)
MCap	4,14,807
Shares o/s	1,986
(a) Value/share (Rs)	209
ACC Mcap based on our TP	4,01,677
ACEM's stake (50.05%) value in ACC	2,01,039
Holding company discount (%)	20
ACEM's stake value in ACC post discount	1,60,831
(b) Value/share (Rs)	81
Target price (Rs) (a+b)	289.9
CMP (Rs)	282.8
Up/(down)side (%)	2.5


Source: Company, DART

Exhibit 7: Volume (mt)



Source: Company, DART

Exhibit 8: Cost/tn (Rs)




Source: Company, DART

Exhibit 9: Realization/tn (Rs)



Source: Company, DART


Exhibit 10: EBITDA/tn (Rs)



Source: Company, DART




Exhibit 11: Power & fuel cost/tn (Rs)



Source: Company, DART

Exhibit 12: Freight cost/tn (Rs)



Source: Company, DART



Revenue	Profit and Loss Account				
Total Expense 95,190 87,253 1,00,409 1,05,142 COGS 68,061 62,931 71,956 74,999 Employees Cost 6,762 6,688 7,490 8,015 Other expenses 20,403 17,634 20,963 22,128 EBIOTA 21,489 26,466 28,567 31,002 Depreciation 5,438 5,212 6,132 7,062 EBIT 16,050 21,254 22,435 23,940 Interest 835 831 831 831 Other Income 4,265 3,720 3,233 3,635 Exc. / E.O. items 0 0 0 0 0 Exc. / E.O. items 0 0 0 0 0 0 0 ERT 19,480 24,144 24,837 26,745 6,732 6,732 6,732 6,745 74,745 74,740 1,856 20,014 0 0 0 0 0 0 0 <th>(Rs Mn)</th> <th>CY19A</th> <th>CY20A</th> <th>CY21E</th> <th>CY22E</th>	(Rs Mn)	CY19A	CY20A	CY21E	CY22E
COGS 68,061 62,931 71,956 74,999 Employees Cost 6,726 6,688 7,490 8,015 Other expenses 20,403 1,7634 20,963 22,128 EBIDTA 21,489 26,466 28,567 31,002 Depreciation 5,438 5,212 6,132 7,062 EBIT 16,050 21,254 22,435 23,940 Interest 835 831 831 831 Other Income 4,265 3,720 3,233 3,635 EKC. JC. Othems 0 0 0 0 0 EBT 19,480 24,144 24,837 6,625 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0 0 0 0 Read 15,285 17,901 18,586 20,014 Minority Interest 0 0 0 0 Res Mn) CY19A CY20A <td< th=""><th>Revenue</th><th>1,16,679</th><th>1,13,719</th><th>1,28,976</th><th>1,36,144</th></td<>	Revenue	1,16,679	1,13,719	1,28,976	1,36,144
Employees Cost 6,726 6,688 7,490 8,015 Other expenses 20,403 17,634 20,963 22,128 EBIDTA 21,489 26,466 28,567 31,002 Depreciation 5,438 5,212 6,132 7,062 EBIT 16,050 21,254 22,435 23,940 Interest 835 831 831 831 Other Income 4,265 3,720 3,233 3,635 Exc. / E.O. items 0 0 0 0 0 Exc. / E.O. items 0 0 0 0 0 0 0 ERT 19,480 24,144 24,837 26,745 6,742 6,252 6,732 6,745 7 7 7 0	Total Expense	95,190	87,253	1,00,409	1,05,142
Other expenses 20,403 17,634 20,963 22,128 EBIDTA 21,489 26,466 28,567 31,002 Depreciation 5,438 5,212 6,132 7,062 EBIT 16,050 21,254 22,435 23,940 Interest 835 831 831 831 Other Income 4,265 3,720 3,233 3,635 Exc. / E.O. items 0 0 0 0 0 EBT 19,480 24,144 24,837 26,745 Tax 4,195 6,243 6,525 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet 4 15,285 17,901 18,586 20,014 Balance Sheet 4 15,285 17,901 18,586 20,014 Restrict Shate 2 <td>COGS</td> <td>68,061</td> <td>62,931</td> <td>71,956</td> <td>74,999</td>	COGS	68,061	62,931	71,956	74,999
EBIDTA 21,489 26,466 28,567 31,002 Depreciation 5,438 5,212 6,132 7,052 EBIT 16,050 21,254 22,435 23,940 Interest 383 831 831 831 Other Income 4,265 3,720 3,233 3,635 Exc. / E.O. items 0 0 0 0 0 BT 19,480 24,144 24,837 26,745 7,624 7,228 7,625 7,722 7,742	Employees Cost	6,726	6,688	7,490	8,015
Depreciation 5,438 5,212 6,132 7,062 EBIT 16,050 21,254 22,435 23,940 Interest 835 831 831 831 Other Income 4,265 3,720 3,233 3,635 Exc. / E.O. items 0 0 0 0 0 EW 19,480 24,144 24,837 26,745 7,672	Other expenses	20,403	17,634	20,963	22,128
EBIT 16,050 21,254 22,435 23,940 Interest 835 831 831 831 Other Income 4,265 3,720 3,233 3,635 EKC. / E.O. items 0 0 0 0 0 EBT 19,480 24,144 24,837 26,745 Tax 4,195 6,243 6,252 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet [Rs Mn] CY19A CY20A CY21E CY22E Correst of Funds Equity Capital 3,971 <t< td=""><td>EBIDTA</td><td>21,489</td><td>26,466</td><td>28,567</td><td>31,002</td></t<>	EBIDTA	21,489	26,466	28,567	31,002
Interest 835 831 831 831 Other Income 4,265 3,720 3,233 3,635 Exc. / E.O. litems 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 6,252 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0 <t< td=""><td>Depreciation</td><td>5,438</td><td>5,212</td><td>6,132</td><td>7,062</td></t<>	Depreciation	5,438	5,212	6,132	7,062
Other Income 4,265 3,720 3,233 3,635 Exc. / E.O. items 0 0 0 0 0 EBT 19,480 24,144 24,837 26,752 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0	EBIT	16,050	21,254	22,435	23,940
Exc. / E.O. items 0 0 0 0 EBT 19,480 24,144 24,837 26,745 Tax 4,195 6,243 6,252 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0 0 0 0 Profit/Loss share of associates 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971 <t< td=""><td>Interest</td><td>835</td><td>831</td><td>831</td><td>831</td></t<>	Interest	835	831	831	831
EBT 19,480 24,144 24,837 26,745 Tax 4,195 6,243 6,252 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0 0 0 0 Profit/Loss share of associates 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971	Other Income	4,265	3,720	3,233	3,635
Tax 4,195 6,243 6,252 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0 0 0 0 Profit/Loss share of associates 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971 3,971 3,971 3,971 Minority Interest 0 0 0 0 Reserves & Surplus 2,18,081 1,99,187 2,13,802 2,29,844 Net Worth 2,22,052 2,03,159 2,17,773 2,33,815 Total Debt 353 436 282 212 Net Deferred Tax Liability 2,161 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Ne	Exc. / E.O. items	0	0	0	0
Tax 4,195 6,243 6,252 6,732 RPAT 15,285 17,901 18,586 20,014 Minority Interest 0 0 0 0 Profit/Loss share of associates 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971 3,971 3,971 3,971 Minority Interest 0 0 0 0 Reserves & Surplus 2,18,081 1,99,187 2,13,802 2,29,844 Net Worth 2,22,052 2,03,159 2,17,773 2,33,815 Total Debt 353 436 282 212 Net Deferred Tax Liability 2,161 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Ne	EBT	19,480	24,144	24,837	26,745
Minority Interest 0 0 0 0 Profit/Loss share of associates 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971<	Tax	4,195	······	6,252	6,732
Profit/Loss share of associates 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971 3,938 42,984 42 2,22,052	RPAT	15,285	17,901	18,586	20,014
Profit/Loss share of associates 0 0 0 0 APAT 15,285 17,901 18,586 20,014 Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971 3,938 42,984 42 2,22,052	Minority Interest	0	0	0	0
Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971 2,24,944 2,24,962 2,24,944 482 212 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000		0	0	0	0
Balance Sheet (Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971 2,24,944 2,24,962 2,24,944 482 212 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000	APAT	15,285	17,901	18,586	20,014
(Rs Mn) CY19A CY20A CY21E CY22E Sources of Funds Equity Capital 3,971 3,981 4,219,918 2,13,802 2,29,844 4,160 1,860 1,860 1,860 1,860 1,860 1,860 1,860 1,860 1,860 1,960 1,971 2,91,818					
Sources of Funds Equity Capital 3,971 3,971 3,971 3,971 3,971 Minority Interest 0 0 0 0 0 Reserves & Surplus 2,18,081 1,99,187 2,13,802 2,29,844 Net Worth 2,22,052 2,03,159 2,17,773 2,33,815 Total Debt 353 436 282 212 Net Deferred Tax Liability 2,161 1,860 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922 1,17,922	Balance Sheet				
Equity Capital 3,971 3,971 3,971 3,971 Minority Interest 0 0 0 0 Reserves & Surplus 2,18,081 1,99,187 2,13,802 2,29,844 Net Worth 2,22,052 2,03,159 2,17,773 2,33,815 Total Debt 353 436 282 212 Net Deferred Tax Liability 2,161 1,860 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922	(Rs Mn)	CY19A	CY20A	CY21E	CY22E
Minority Interest 0 0 0 0 Reserves & Surplus 2,18,081 1,99,187 2,13,802 2,29,844 Net Worth 2,22,052 2,03,159 2,17,773 2,33,815 Total Debt 353 436 282 212 Net Deferred Tax Liability 2,161 1,860 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45	Sources of Funds				
Reserves & Surplus 2,18,081 1,99,187 2,13,802 2,29,844 Net Worth 2,22,052 2,03,159 2,17,773 2,33,815 Total Debt 353 436 282 212 Net Deferred Tax Liability 2,161 1,860 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Liabilities & Provisions	Equity Capital	3,971	3,971	3,971	3,971
Net Worth 2,22,052 2,03,159 2,17,773 2,33,815 Total Debt 353 436 282 212 Net Deferred Tax Liability 2,161 1,860 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 1,17,922 Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Liabilities & Provisions 45,342 49,360 50,649 53,306	Minority Interest	0	0	0	0
Total Debt 353 436 282 212 Net Deferred Tax Liability 2,161 1,860 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,27,922 1,27,922 1,27,922 1,27,922	Reserves & Surplus	2,18,081	1,99,187	2,13,802	2,29,844
Net Deferred Tax Liability 2,161 1,860 1,860 1,860 Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,	Net Worth	2,22,052	2,03,159	2,17,773	2,33,815
Total Capital Employed 2,24,565 2,05,454 2,19,915 2,35,887 Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893	Total Debt	353	436	282	212
Applications of Funds Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 Sub total Net Current Assets 37,464 9,480 18,809 30,843	Net Deferred Tax Liability	2,161	1,860	1,860	1,860
Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 Sub total Net Current Assets 37,464 9,480 18,809 30,843	Total Capital Employed	2,24,565	2,05,454	2,19,915	2,35,887
Net Block 58,125 59,315 79,183 77,122 CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 Sub total Net Current Assets 37,464 9,480 18,809 30,843	Applications of Funds				
CWIP 11,087 18,737 4,000 10,000 Investments 1,17,890 1,17,922 1,17,922 1,17,922 Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 Sub total Net Current Assets 37,464 9,480 18,809 30,843		58 125	50 215	79 183	77 122
Investments 1,17,890 1,17,922 1,0,614 1,0,614 1,0,614 1,0,614 1,0,614 <		······	······		
Current Assets, Loans & Advances 82,806 58,839 69,458 84,149 Inventories 9,541 7,466 10,085 10,614 Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 Sub total Net Current Assets 37,464 9,480 18,809 30,843					
Inventories 9,541 7,466 10,085 10,614		·····			
Receivables 5,132 1,915 5,425 5,710 Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 sub total Net Current Assets 37,464 9,480 18,809 30,843					
Cash and Bank Balances 46,995 29,243 30,356 42,995 Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 sub total Net Current Assets 37,464 9,480 18,809 30,843					
Loans and Advances 45 44 49 52 Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 sub total Net Current Assets 37,464 9,480 18,809 30,843		·····	······		
Other Current Assets 21,093 20,170 23,543 24,779 Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 sub total Net Current Assets 37,464 9,480 18,809 30,843		·····	••••••		
Less: Current Liabilities & Provisions 45,342 49,360 50,649 53,306 Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 sub total Net Current Assets 37,464 9,480 18,809 30,843					
Payables 9,360 8,809 9,894 10,413 Other Current Liabilities 35,982 40,551 40,755 42,893 sub total Net Current Assets 37,464 9,480 18,809 30,843	Other Current Assets	21,093	20,170	23,343	24,773
Other Current Liabilities 35,982 40,551 40,755 42,893 sub total Net Current Assets 37,464 9,480 18,809 30,843	Less: Current Liabilities & Provisions	45,342	49,360	50,649	53,306
Other Current Liabilities 35,982 40,551 40,755 42,893 sub total Net Current Assets 37,464 9,480 18,809 30,843	Payables	9,360	8,809	9,894	10,413
sub total Net Current Assets 37,464 9,480 18,809 30,843			·····	40,755	42,893
Net Current Assets 37,464 9,480 18,809 30,843	sub total				
	Net Current Assets	37,464	9,480	18,809	30,843
TOTAL ASSETS 2,24,565 2,05,454 2,19,915 2,35,88/	Total Assets	2,24,565	2,05,454	2,19,915	2,35,887

E – Estimates



Important Ratios	0/404	CV204	0/245	01/00
Particulars (a)	CY19A	CY20A	CY21E	CY22I
(A) Margins (%)				
Gross Profit Margin	41.7	44.7	44.2	44.9
EBIDTA Margin	18.4	23.3	22.1	22.8
EBIT Margin	13.8	18.7	17.4	17.6
Tax rate	21.5	25.9	25.2	25.2
Net Profit Margin	13.1	15.7	14.4	14.7
(B) As Percentage of Net Sales (%)				
COGS	58.3	55.3	55.8	55.1
Employee	5.8	5.9	5.8	5.9
Other	17.5	15.5	16.3	16.3
(C) Measure of Financial Status				
Gross Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	19.2	25.6	27.0	28.8
Inventory days	30	24	29	28
Debtors days	16	6	15	15
Average Cost of Debt	222.8	210.6	231.2	336.1
Payable days	29	28	28	28
Working Capital days	117	30	53	83
FA T/O	2.0	1.9	1.6	1.8
(D) Measures of Investment				
AEPS (Rs)	7.7	9.0	9.4	10.1
CEPS (Rs)	10.4	11.6	12.4	13.6
DPS (Rs)	2.4	18.0	2.0	2.0
Dividend Payout (%)	31.3	199.7	21.4	19.8
BVPS (Rs)	111.8	102.3	109.7	117.8
RoANW (%)	7.1	8.4	8.8	8.9
RoACE (%)	7.3	8.7	9.1	9.1
RoAIC (%)	9.0	12.0	12.3	12.5
(E) Valuation Ratios	3.0	12.0	12.5	12.0
CMP (Rs)	283	283	283	283
P/E	36.7	31.4	30.2	28.1
Mcap (Rs Mn)	5,61,540	5,61,540	5,61,540	5,61,540
MCap/ Sales	4.8	4.9	4.4	4.1
EV	5,14,898	5,32,733	5,31,467	5,18,758
EV/Sales	4.4	4.7	4.1	3.8
EV/EBITDA P/BV	24.0 2.5	20.1	18.6	16.7
		······	2.6	2.4
Dividend Yield (%)	0.9	6.4	0.7	0.7
(F) Growth Rate (%)		/2 ->		
Revenue	2.7	(2.5)	13.4	5.6
EBITDA	13.6	23.2	7.9	8.5
EBIT	19.5	32.4	5.6	6.7
PBT	29.3	23.9	2.9	7.7
APAT	27.4	17.1	3.8	7.7
EPS	27.4	17.1	3.8	7.7
Cash Flow				
	CV104	CV20A	CV21F	CV22
(Rs Mn)	CY19A	CY20A	CY21E	CY22E
CFO	24,846	26,062	15,363	25,499
CFI	(7,366)	(6,415)	(9,457)	(8,202
CFF	(3,888)	(37,604)	(4,794)	(4,658
FCFF	13,682	16,208	4,101	14,499
Opening Cash	45,123	29,243	30,356	42,995
Closing Cash	46,995	29,243	30,356	42,995



DART RATING MATRIX

Total Return Expectation (12 Months)

Buy	> 20%
Accumulate	10 to 20%
Reduce	0 to 10%
Sell	< 0%

Rating and Target Price History



Month	Rating	TP (Rs.)	Price (Rs.)
Feb-20	Accumulate	242	205
Mar-20	Accumulate	186	142
Mar-20	Accumulate	186	148
Apr-20	Accumulate	192	172
Jul-20	Accumulate	257	201
Oct-20	Accumulate	257	254
Dec-20	Accumulate	257	253

^{*}Price as on recommendation date

DART Team

Purvag Shah	Managing Director	purvag@dolatcapital.com	+9122 4096 9747			
Amit Khurana, CFA	Head of Equities	amit@dolatcapital.com	+9122 4096 9745			
CONTACT DETAILS						
Equity Sales	Designation	E-mail	Direct Lines			
Dinesh Bajaj	VP - Equity Sales	dineshb@dolatcapital.com	+9122 4096 9709			
Kapil Yadav	VP - Equity Sales	kapil@dolatcapital.com	+9122 4096 9735			
Yomika Agarwal	VP - Equity Sales	yomika@dolatcapital.com	+9122 4096 9772			
Jubbin Shah	VP - Derivatives Sales	jubbins@dolatcapital.com	+9122 4096 9779			
Ashwani Kandoi	AVP - Equity Sales	ashwanik@dolatcapital.com	+9122 4096 9725			
Lekha Nahar	AVP - Equity Sales	lekhan@dolatcapital.com	+9122 4096 9740			
Equity Trading	Designation	E-mail				
P. Sridhar	SVP and Head of Sales Trading	sridhar@dolatcapital.com	+9122 4096 9728			
Chandrakant Ware	VP - Sales Trading	chandrakant@dolatcapital.com	+9122 4096 9707			
Shirish Thakkar	VP - Head Domestic Derivatives Sales Trading	shirisht@dolatcapital.com	+9122 4096 9702			
Kartik Mehta	Asia Head Derivatives	kartikm@dolatcapital.com	+9122 4096 9715			
Dinesh Mehta	Co- Head Asia Derivatives	dinesh.mehta@dolatcapital.com	+9122 4096 9765			
Bhavin Mehta	VP - Derivatives Strategist	bhavinm@dolatcapital.com	+9122 4096 9705			



Analyst(s) Certification

The research analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

I. Analyst(s) and Associate (S) holding in the Stock(s): (Nil)

II. Disclaimer:

This research report has been prepared by Dolat Capital Market Private Limited. to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies) solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of Dolat Capital Market Private Limited. This report has been prepared independent of the companies covered herein. Dolat Capital Market Private Limited. and its affiliated companies are part of a multi-service, integrated investment banking, brokerage and financing group. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, financing or any other advisory services to the company(ies) covered herein. Dolat Capital Market Private Limited. and/or its affiliated company(ies) might have received or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services. Research analysts and sales persons of Dolat Capital Market Private Limited. may provide important inputs to its affiliated company(ies) associated with it. While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and Dolat Capital Market Private Limited. does not warrant its accuracy or completeness. Dolat Capital Market Private Limited. may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision. The investment discussed or views expressed herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and Dolat Capital Market Private Limited. reserves the right to make modifications and alterations to this statement as they may deem fit from time to time. Dolat Capital Market Private Limited. and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction. This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Dolat Capital Market Private Limited. and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

For U.S. Entity/ persons only: This research report is a product of Dolat Capital Market Private Limited., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Dolat Capital Market Private Limited. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person or entity.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Dolat Capital Market Private Limited. has entered into an agreement with a U.S. registered broker-dealer Ltd StoneX Financial Inc.("StoneX"). Transactions in securities discussed in this research report should be effected through StoneX Financial Inc.("StoneX") or another U.S. registered broker dealer/Entity as informed by Dolat Capital Market Private Limited. from time to time.



Dolat Capital Market Private Limited.

Corporate Identity Number: U65990DD1993PTC009797

Member: BSE Limited and National Stock Exchange of India Limited.

SEBI Registration No: BSE – INZ000274132, NSE - INZ000274132, Research: INH000000685

Registered office: Office No. 141, Centre Point, Somnath, Daman – 396 210, Daman & Diu

Board: +9122 40969700 | Fax: +9122 22651278 | Email: research@dolatcapital.com | www.dolatresearch.com